Imidazolyl progesterone antagonists
Inventors
Nickisch, Klaus • Elger, Walter • Santhamma, Bindu
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are imidazolyl compounds which either act as pure antiprogestins and methods of using such pure antagonists for gynecological indications and breast cancer.
Core Innovation
The patent describes imidazolyl progesterone antagonists as pure antiprogestins lacking partial agonist activity. The compounds are presented as having a progesterone receptor profile associated with progesterone antagonism rather than partial agonistic behavior, and the background discusses the need for antiprogestin activity without partial agonist activity in contrast to known antiprogestins such as mifepristone and ulipristal.
The core chemical innovation is an imidazolyl progesterone antagonist compound framework defined by formula (I), including substituent variables X, R1-R4, R5, R6, and R7. In particular, R5 is an N-imidazolyl group and R7 is defined by a radical of formula CnFmHo with specified constraints relating n, m, and o, with additional embodiments illustrated by specific imidazolyl estrane derivatives Ia-Ie with fluorinated substituents.
The patent also describes steroidal intermediates and final compounds, including imidazole-containing iodophenyl-imidazole derivatives and related structures. Transformation steps are described for converting intermediates into compounds, and nuclear receptor profiling results are reported for antagonist activity of the disclosed imidazole-containing compounds at progesterone and glucocorticoid receptors, with comparative percentages relative to RU486=100%.
Claims Coverage
The claim coverage includes independent claims defining compounds having the structure of formula (I) with imidazolyl substitution and constrained fluorinated radical substituent selection, together with linkage options for certain substituent positions. Overall, the claims present two inventive features centered on a common formula (I) scaffold and its specified substituents.
Formula (I) with constrained substituent variables
A compound having the structure of formula (I) wherein X is O or H; R1, R2, R3, and R4 are each independently hydrogen, alkyl, cycloalkyl, or halogen, with linkage options for R1 and R2, and for R3 and R4; R5 is an N imidazolyl group optionally substituted by one or more alkyl groups; R6 is a free, etherified or esterified hydroxyl group; and R7 is a radical of formula CnFmHo with defined constraints on n, m, and o.
Formula (I) with imidazolyl substitution and specific R6-R7 depiction options
A compound having the structure of formula (I) wherein X is O or H; R1, R2, R3, and R4 are each independently hydrogen, alkyl, cycloalkyl, or halogen, with linkage options for R1 and R2 together, and for R3 and R4 together; R5 is an N imidazolyl group that is optionally substituted with alkyl groups; and R6 and R7 are as specified by the claim set via provided structural depictions.
Overall, the claim coverage is concentrated on a common formula (I) progesterone antagonist scaffold featuring an N-imidazolyl group (R5) and a hydroxyl defined as free, etherified or esterified (R6), together with a fluorinated radical substituent (R7) defined by CnFmHo constraints and further narrowed to specific illustrated structures via structural depictions.
Stated Advantages
Described as pure antiprogestins lacking partial agonist activity.
Associated with progesterone antagonism without partial agonistic behavior.
Nuclear receptor profiling indicates antagonist activity of compounds Ia-Ie at progesterone and glucocorticoid receptors, reported as percentages relative to RU486=100%.
Documented Applications
Fertility control.
Hormone dependent breast cancer.
Nuclear receptor profiling assays for antagonist activity at progesterone and glucocorticoid receptors using SelectScreen and GeneBLAzer Beta-lactamase reporter systems, with RU486 used as a reference and results reported in Table I for compounds Ia-Ie.
Interested in licensing this patent?